お知らせ • May 21
Dancann Pharma A/S Receives Regulatory Approval for Bedrolite and Bedrobinol from the Danish Medicines Agency Under the Danish Pilot Programme DanCann Pharma A/S announced that the Company has obtained approval from the Danish Medicines Agency for the distribution of Bedrolite®? and Bedrobinol®? under the Danish Medicines Agency. The approval of these new products is in line with the Company's communicated guidance and is expected to have a positive impact on sales performance going forward. DanCann Pharma has received confirmation of regulatory approval for the distribution of two additional products in the Danish medicinal cannabis market from the Danish Medicines Agency. This regulatory milestone further strengthens DanCann Pharma's strategic positioning and leadership within Denmark's tightly regulated framework for medicinal cannabis and underscores the Company's ongoing commitment to broadening patient access to standardized, high-quality cannabinoid-based therapies. Bedrolite®? and bedrobinol®? Bedrolite®? represents the first Cannabidiol ("CBD")-dominant granulate product to be approved under the Pilot Programme in Denmark. The product contains approximately 9% CBD and less than 1% delta-9-tetrahydrocannabinol ("THC"). Inhalation as a delivery method allows for rapid onset of action, typically within 5-10 minutes, which is advantage for managing acute symptoms. The method also enables precise self-titration by patients and avoids first-pass hepatic metabolism, thereby improving bioavailability compared to oral formulations (e.g. oils, extracts and tinctures). Under the current framework of the Danish Pilot Programme for medicinal cannabis, the products are prescribable by all licensed medical practitioners and are eligible for public reimbursement in accordance with the reimbursement scheme established under the Pilot Programme for medicinal cannabis. Under the Danish pilot Programme for medicinal cannabis, patients are eligible for government reimbursement covering 50% of their annual treatment costs, up to a maximum of DKK 20,000 per year. The expected retail price for the newly approved products (Bedrolite®? and Bedrombinol®? in 5-gram units) is approximately DKK 500.00, inclusive of VAT and pharmacy fees. After reimbursement, the effective out-of-pocket cost to the patient is approximately DKK 250.00 per unit--equivalent to around DKK 50.00 per gram. This cost may be further reduced for patients who are members of the private health insurance scheme "Danmark", depending on their membership group and applicable coverage terms. お知らせ • Apr 11
DanCann Pharma A/S to Report Q1, 2025 Results on Apr 28, 2025 DanCann Pharma A/S announced that they will report Q1, 2025 results on Apr 28, 2025 お知らせ • Apr 05
DanCann Pharma A/S Provides Financial Guidance for 2025 DanCann Pharma A/S provided Financial guidance for 2025. For the period, the company expects revenue in the range of DKK 10.0 million to DKK 12.5 million. お知らせ • Mar 28
DanCann Pharma A/S to Report Fiscal Year 2024 Results on Apr 04, 2025 DanCann Pharma A/S announced that they will report fiscal year 2024 results on Apr 04, 2025 お知らせ • Feb 17
DanCann Pharma A/S Provides Earnings Guidance for the Year 2025 and 2026 DanCann Pharma A/S provided earnings guidance for the year 2025 and 2026. In 2025, The company anticipates reaching between DKK 10.0 million and DKK 12.5 million, representing a YoY increase of 29.9% to 62.3% compared to the realized revenue (NET) of DKK 7.7 Million in 2024.
Looking further ahead, its 2026 revenue guidance is set at DKK 20.0 million to DKK 25.0 million, a doubling (+100% YoY) of 2025 revenue, underlining the scalability of its business model and the anticipated impact of strategic initiatives. お知らせ • Dec 11
DanCann Pharma A/S Elects Jes Lunde as Additional Member of the Board of Directors DanCann Pharma A/S at its extraordinary general meeting was held on 10 December 2024, approved Jes Lunde shall be elected as the additional member of the board of directors. お知らせ • Oct 31
DanCann Pharma A/S to Report Q3, 2024 Results on Nov 29, 2024 DanCann Pharma A/S announced that they will report Q3, 2024 results on Nov 29, 2024 お知らせ • Aug 14
DanCann Pharma A/S Revises Earnings Guidance for 2024 DanCann Pharma A/S revised earnings guidance for 2024. For the period, the company now expects revenue in the range of DKK 11.0 million to DKK 12.0 million, adjusted from the previous DKK 13.3 million. The guidance has been adjusted due to delays in the processes of the Danish Medicines Agency, which have also affected the Company's ongoing product approvals. As a result, the Company has slightly revised down its revenue expectations for 2024. お知らせ • Aug 01
DanCann Pharma A/S to Report Q2, 2024 Results on Aug 30, 2024 DanCann Pharma A/S announced that they will report Q2, 2024 results on Aug 30, 2024 お知らせ • Jun 20
DanCann Pharma A/S Provides Revenue Guidance for the Year 2024 DanCann Pharma A/S provided revenue guidance for the year 2024. For the year, the company expected to generate approximately DKK 10 million - DKK 11 million in revenue. お知らせ • May 03
DanCann Pharma A/S to Report Q1, 2024 Results on May 31, 2024 DanCann Pharma A/S announced that they will report Q1, 2024 results on May 31, 2024 お知らせ • May 01
DanCann Pharma A/S, Annual General Meeting, May 30, 2024 DanCann Pharma A/S, Annual General Meeting, May 30, 2024. お知らせ • Apr 04
Dancann Pharma A/S to Report Q3, 2024 Results on Apr 17, 2024 Dancann Pharma A/S announced that they will report Q3, 2024 results on Apr 17, 2024